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Factor Va is an  essential cofactor in  factor Xa-cata- 
lyzed prothrombin  activation.  Purified human factor 
Va appears  to consist of a heavy  chain (M, 105,000) 
and a light chain doublet with M. = 74,000 and = 
71,000. We separated  factor Va by chromatography on 
a Mono-S  column into  two  fractions, designated factors 
Val and Vaz. Factor Val contains  the  light  chain  with 
M, = 74,000, and  factor Vaz exclusively contains  the 
light  chain  with M, = 71,000. The  two  forms of factor 
Va express different cofactor activities when pro- 
thrombin  is  activated at low phospholipid concentra- 
tions or on membranes containing low amounts of phos- 
phatidylserine in phosphatidylcholine. Compared with 
factor Vaz, much higher amounts of factor Val are 
required  for  factor Xa. Va complex formation at the 
membrane surface. Once incorporated into the pro- 
thrombinase complex, factors Val and Vaz are equally 
active in prothrombin  activation.  This  indicates that 
the  two  forms of factor Va do not differ  in  their  ability 
to promote the catalytic activity of factor Xa or to 
interact  with  prothrombin.  Direct  binding  experiments 
show that the different cofactor activities are ex- 
plained by a  greatly  impaired  ability of factor Val to 
bind to negatively charged membranes. Factor V is 
also separated  into  two  protein  peaks  after chromatog- 
raphy on a Mono-S column. Upon incubation with 
thrombin,  the first peak yields factor Val and  the sec- 
ond peak  factor Vaz. The same two  forms of factor Va 
were  generated when freshly  prepared plasma samples 
or platelet suspensions were  treated  with  thrombin. 
This shows that  the heterogeneity of the  light  chain 
domain is an intrinsic property of both plasma and 
platelet  factor V. It is hypothesized that  the heteroge- 
neity is caused by small differences in the  carboxyl- 
terminal C2 domain of factor  V  that are introduced as 
the  result of post-ribosomal processing. 
Activated blood coagulation factor  V  (factor Va) plays an 
essential role as cofactor in the conversion of prothrombin 
into thrombin by the serine protease factor Xa. Factor Va 
accelerates factor Xa-catalyzed prothrombin  activation four 
to five orders of magnitude by causing a 1000-fold increase of 
the catalytic capacity ( kcat) of factor Xa (1,2)  and by promot- 
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ing the binding of both factor Xa  and  prothrombin to proco- 
agulant membranes (1,3, 4). 
Factor Va is generated from the pro-cofactor, factor V, 
which circulates in plasma as  a single chain glycoprotein with 
M, of about 330,000 (5, 6). Factor V has  little  or no procoag- 
ulant  activity (1) and is converted into factor Va after prote- 
olysis of specific peptide bonds, which, among others,  can be 
catalyzed by thrombin (5-7). Thrombin-activated factor V is 
a two-chain molecule (7), that consists of a heavy and  a light 
chain held together by a  tightly bound calcium ion (8,9). The 
heavy chain is derived from the amino-terminal region of 
factor V and has an Mr of 105,000. The light chain originates 
from the carboxyl-terminal region and  appears on SDS-poly- 
acrylamide gels as  a doublet with apparent M, of 71,000 and 
74,000, both in case of human (7) and bovine factor Va 
(10, 11). 
There is as yet no good explanation for the heterogeneity 
of the light chain of factor Va. It is likely,  however, that  the 
structural basis for the light chain doublet has to be sought 
in i  carboxyl-terminal region, since large parts of the amino- 
terminal region of the light chain (with M, up to 62,000) 
appear  as single bands  after SDS-gel electrophoretic analysis 
(11, 12). 
In  this paper, we show that  the heterogeneity of the car- 
boxyl-terminal domain of the light chain region of factor Va 
is already observed in factor V present in fresh plasma and 
platelet samples. We further  report  the  separation of factor 
Va into two fractions that  are homogeneous with respect to 
their light chain composition. The factor Va preparation with 
the M, 71,000 light chain is characterized by a more efficient 
incorporation in  the prothrombinase complex than  the factor 
Va that contains the light chain with M, = 74,000. This 
difference in cofactor function appears to be due to  different 
binding affinities for procoagulant membranes. 
EXPERIMENTAL  PROCEDURES 
Materials-Bovine serum albumin, chicken egg albumin (ovalbu- 
min), soybean trypsin  inhibitor  (type IS), bovine brain PS,’ egg-yolk 
PC, Russel’s viper venom, Hepes, and Tris were purchased from 
Sigma. DOPC and  DOPS were obtained from Avanti Polar Lipids, 
Pelham, AL. S2238 (D-Phe-(pipecoly1)-Arg-pNA), S2337 (Ile-Glu- 
(piperidyl)-Gly-Arg-pNA), and I2581 (N-dansyl-(p-guanidine)-phen- 
ylalanine-piperidide hydrochloride) were supplied by  AB Kabi Diag- 
nostica, Stockholm, Sweden. PPACK (D-Pro-Phe-Arg-CH,Cl) was 
obtained from Calbiochem, and  p-NPGB was from Nutritional Bio- 
chemicals. Column materials and  FPLC equipment used for protein 
’ The abbreviations used are: PS, phosphatidylserine; PC, pbos- 
phatidylcholine; DOPS, 1,2-Dioleoyl-sn-glycero-3-phosphoserine; 
DOPC, 1,2-dioleoyl-sn-glycero-3-phosphocholine; BSA, bovine serum 
albumin; FPLC, fast liquid protein chromatography; PAGE, poly- 
acrylamide gel electrophoresis;p-NPGB,p-nitrophenyl-p’-guanidino- 
benzoate hydrochloride; RVV-X, purified factor X activator from 
Russel’s viper venom. 
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Heterogeneity of Human Factor Vu 21131 
purification were purchased from Pharmacia, Uppsala, Sweden. 
Proteins-The human coagulation factors used in this study were 
purified from fresh frozen plasma. Human  prothrombin and factor  X 
were purified according to DiScipio et al. (13). Human  thrombin was 
prepared from prothrombin activation mixtures by the method of 
Pletcher and Nelsestuen (14). Human  factor Xa was obtained from 
purified factor  X after activation with RVV-X and isolation from the 
activation mixture by affinity chromatography on soybean trypsin 
inhibitor-Sepharose (15). RVV-X was purified from Russel’s viper 
venom according to Schiffman et al. (16). Human factor V was 
purified essentially as described by Dahlback ( 5 )  with minor modifi- 
cations (17). Factor Va  was prepared by incubating factor V (0.3 mg/ 
ml) for 20 min with 30 nM thrombin  in  a buffer containing 10 mM 
Hepes pH 7.5,50 mM NaCl, and 5 mM CaCl2. After activation, 60 nM 
PPACK was added to inhibit  thrombin. The factor Va preparation 
was subsequently applied to a 1-ml prothrombin-CL4B-Sepharose 
column and eluted with a  linear gradient of 50-500 mM NH4Cl in 10 
mM Hepes pH 7.5. Factor Va eluted at  260 mM NH4Cl. The factor 
Va-containing fractions were pooled and diluted in  a buffer containing 
25 mM Hepes pH 7.5, 100 mM NH4Cl, 5 mM CaC12, and 5 mg/ml 
BSA. Prothrombin,  factor Xa, factor V, and factor Va were stored at 
judged by SDS-PAGE according to Laemmli (18). 
-80 “C. Protein  preparations were homogeneous and >95% pure as 
Separation of the Two Forms of Factor Va (Val and Vad-The 
factor Va obtained from the prothrombin-CL4B-Sepharose column 
(see previous paragraph) was further subjected to fast  protein liquid 
chromatography (FPLC) on a Mono-S column (HR 5 / 5 )  at room 
temperature. The flow rate during the whole purification procedure 
was 0.5 ml/min. After application of 0.6-mg factor Va, the column 
was washed with 15 ml of a buffer containing 25 mM Hepes pH 7.5, 
50 mM NHICI, and 5 mM CaC12. No factor Va activity eluted during 
the application and wash procedure. The Mono-S column was then 
developed with 15 ml of a  linear  gradient (50-1000 mM NH4Cl)  in 
the same buffer. Factor Va activity eluted from the column in two 
well separated  protein peaks at  450 and 750 mM NH4CI. The first 
factor Va peak contained the light  chain with M, = 74,000 (factor 
Val), and  the second peak consisted of factor Va with a  light  chain 
with M, = 71,000 (factor Vaz). The two factor Va-containing peaks 
were  pooled separately and contained  pure and homogeneous factor 
Va as judged by SDS-PAGE according to Schagger and von Jagow 
(19). In a large number of factor Va preparations isolated from 
different batches of human  plasma, the amount of protein  present in 
peak 1 was about half that present  in peak 2. 
Separation and identification of different  factor  V forms present 
in purified factor V  preparations and in plasma and platelet samples 
were accomplished by the same procedure described in the legends to 
the figures. 
Gel Electrophoretic Techniques-Factor Va preparations and  the 
activation patterns of factor V  activated with thrombin were analyzed 
by SDS-PAGE  in the presence of Tricine according to Schagger and 
von Jagow (19). This electrophoretic technique has the advantage 
that  the separation of protein  bands  in the gel is hardly affected by 
the ionic strength of the samples. 
Protein Concentrations-Protein concentrations were determined 
according to Lowry et al. (20). Molar thrombin and factor  Xa concen- 
trations were determined by active site  titration with p-NPGB (21, 
22). Prothrombin concentrations were determined after complete 
activation of prothrombin with Echis carinatus venom and  quantita- 
tion of thrombin with p-NPGB. Factor  V  concentrations were esti- 
mated from the absorbance at 280 nm using an AZW 1% of 8.9 (6). 
Factor Va concentrations were determined as described by Lindhout 
et al. (3). 
phospholipids dissolved in CHC13/CH30H (1/1, v/v) were mixed in  a 
Phospholipid Vesicle Preparations-Appropriate quantities of 
glass tube and dried under  a mild flow of Nz. The phospholipids were 
suspended in 2 ml of buffer (25 mM Hepes pH 7.5, 175 mM NaCl) 
and vigorously vortexed for 1 min. The phospholipid suspension was 
subsequently sonicated for 10 min at 0 “C using an MSE  Mark I1 150 
W ultrasonic disintegrator set  at 8 pm peak-to-peak amplitude. Phos- 
pholipid concentrations were determined by phosphate  analysis (23). 
Factor Va Assay-Factor Va was quantitated by measuring its 
cofactor activity in factor Xa-catalyzed prothrombin activation at  
saturating concentrations of factor Xa, phospholipid vesicles, and 
prothrombin and  at a limiting amount of factor Va (17). The factor 
Va concentration in the assay mixture was calculated from the  rate 
of prothrombin  activation using a  turnover  number of 6000 mol of 
prothrombin  activated/min/mol of factor Xa. Va complex (24). 
It should be emphasized that  the  quantitation of the two forms of 
factor Va (Val and Vaz) that are studied in this paper is correct 
despite the fact that there are reaction conditions at which they 
express different cofactor activities in  prothrombin activation. This 
is inherent to the  fact  that  the high concentrations of factor Xa, 
prothrombin, and phospholipids used in the assay system nullify the 
differences in cofactor activities (see “Results,” Table  I). 
Kinetic Data Analysis-Complex formation between membrane- 
bound factors  Xa and Va  was determined by measuring the  rate of 
prothrombin activation in  the presence of phospholipid vesicles at a 
fixed limiting concentration of factor Xa and varying amounts of 
factor Va. Factor Va, factor Xa, and phospholipid vesicles were 
preincubated for 5 min at 37 “C in 25 mM Hepes pH 7.5, 175 mM 
NaCl, 2 mM CaClZ, and 5 mg/ml BSA. Activation was started by 
addition of prothrombin  (preincubated at 37 ‘C in the same buffer). 
Rates of prothrombin  activation were determined with the chromo- 
genic substrate S2238 (2). The  apparent K d  for dissociation of the 
membrane-bound factor Xa. Va complex (KwJ and  the prothrombin- 
converting activity of this complex at [factor Va]+m (VV,) were 
obtained from a plot of the rate of prothrombin activation as a 
function of the factor Va concentration that was fitted to  the equation 
for a single site binding isotherm (hyperbola) in the computer pro- 
gram “Enzfitter.” 
The kinetic  parameters of factor Xa-catalyzed prothrombin  acti- 
vation ( K ,  for prothrombin and V,. of prothrombin  activation) were 
determined by measuring the  rate of thrombin formation at varying 
prothrombin  concentrations  in the presence of a fixed phospholipid 
concentration, a limiting amount of factor Xa, and a saturating 
concentration factor Va under conditions described in the previous 
paragraph. The kinetic parameters were obtained by fitting the  data 
to  the Michaelis-Menten equation using the Enzfitter computer pro- 
gram. 
Binding Studies-Binding parameters for factor Va-membrane 
association were determined on planar phospholipid bilayers. The 
concentrations of membrane-bound factor Va were determined by 
ellipsometry (25), and  the free factor Va concentrations were deter- 
mined with the functional assay described above. Amounts of phos- 
pholipid-bound factor Va were plotted as a function of the free factor 
Va concentration, and  the binding parameters ( K d  and number of 
membrane binding sites) were obtained by fitting the data to the 
equation for a single site binding isotherm in the computer program 
Enzfitter. 
RESULTS 
Separation of Two Forms of Factor Va by FPLC on a Mono- 
S Column-Purified human factor V was converted into factor 
Va with thrombin. Factor Va was subsequently separated 
from the activation  fragments by chromatography on a  pro- 
thrombin-Sepharose column (cf. Ref. 26). SDS-gel electro- 
phoretic analysis showed that  this procedure yielded a  pure 
factor Va preparation that consisted of a heavy chain with M, 
of 105,000 and  the characteristic light chain doublet migrating 
in  the 71,000-74,000 molecular weight  region (Fig. 1, lane 2). 
Although anion exchangers are usually employed in the 
purification of factor V and Va, it appears that  the light chain 
of factor Va is a basic protein with a high affinity for cation 
exchangers (3, 11). Fig. 2 shows that factor Va also bound to 
a Mono-S column. Subsequent  elution with a NH,C1 gradient 
yielded two protein  peaks with factor Va activity. SDS-PAGE 
analysis showed that  the  first peak consisted of factor Va 
molecules with a light chain of  M, = 74,000 (Fig. 1, fractions 
79-81) and  that  the factor Va that eluted in the second peak 
contained the light chain with M, = 71,000  (Fig. 1, fractions 
87-90). In  the  text  that follows, we will designate the factor 
Va present  in the  first peak, factor Val, while the factor Va 
present  in the second peak will  be called factor Vaz. 
Separation of Two Forms of Factor V on a Mono-S Col- 
umn-Nonactivated human factor V showed a chromato- 
graphic behavior that strongly resembled factor Va. Factor V 
also bound t o  the Mono-S column and  eluted  as  a double peak 
when the column was  developed with an NH&l gradient (Fig. 
3A). Incubation of the protein  fractions with thrombin yielded 
two factor Va activity peaks, which, as shown by SDS-PAGE 
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FIG. 1. Gel electrophoretic analysis of  factor V and Va prep- 
arations. Factor V, thrombin-activated factor V, and factors Val and 
Vaz that eluted from the Mono-S column were subjected to SDS- 
PAGE on  slab gels containing 7.5% acrylamide (19). 20 pl of a factor 
V- or Va-containing sample (0.6-5 pg protein) was mixed with 5 pl 
of electrophoresis sample buffer and applied to  the gel. Lane 1, factor 
V; lane 2, thrombin-activated factor V (factor Va); fractions 79-81 = 
factor Val; fractions 87-90 = factor Vas. Gels were stained with 
Coomassie Brilliant Blue R-250. 
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FIG. 2. Chromatography  of factor Va on Mono-S. Factor Va 
obtained from prothrombin CL 4B-Sepharose was diluted to 0.6 mg/ 
20 ml in  a buffer containing 25 mM Hepes pH 7.5, 50 mM NHIC1, 
and 5 mM CaClZ and was applied to a Mono-S column (HR 5/51 that 
was equilibrated with the same buffer. After application of factor Va, 
the column was washed with 15 ml of buffer. Factor Va was subse- 
quently eluted from the column with 15 ml of a linear gradient (50- 
1000 mM NH,Cl) in 25 mM Hepes pH 7.5,5 mM CaCl2. Fractions (0.5 
ml) were collected and assayed for factor Va activity (0) as described 
under “Experimental Procedures.” Fractions from peak 1 (79-81) 
and peak 2 (87-90) were subjected to SDS-PAGE (Fig. 1). 
analysis (Fig. 3B) ,  were highly enriched in  the 74,000 and 
71,000 Da light chains. This experiment indicates that  the 
light  chain doublet present  on SDS gels of factor Va prepa- 
rations does not result from additional peptide bond cleavages 
that occur during the activation of factor V by thrombin  but 
shows that the heterogeneity in the light chain domain is 
already present  in  factor V. 
Structural Properties of Plasma and Platelet Factor V Pres- 
ent in Freshly Collected Blood Samples-The experiments 
presented in the previous paragraph strongly suggest that 
purified factor V  preparations already contain two forms of 
factor V. However, this does not necessarily mean that  there 
are also two forms of factor V  circulating in plasma,  since it 
is possible that  the heterogeneity of purified factor  V  prepa- 
rations results from reactions that occurred during the puri- 
fication procedure. In order to exclude this possibility, we 
performed the following experiment. Freshly collected blood 
samples were subjected to two centrifugation steps, which 
successively removed the erythrocytes and blood platelets  and 
yielded platelet-poor plasma. The platelet pellet was resus- 
pended in buffer, and thrombin was added to both the platelet- 
poor plasma and  to  the platelet suspension. The generation 
of factor Va activity was  followed, and, after complete acti- 
vation of factor V, the plasma and  platetet suspensions were 
diluted and applied to a Mono-S column. Development of this 
column with a linear NH,Cl gradient yielded, both for the 
plasma (Fig. 4) and  the platelet sample (data  not shown), two 
factor Va activity peaks that eluted between 450-500 and 
700-750 mM NH4Cl, respectively. 
From the fact that  the time interval between taking the 
blood samples and separating the plasma and platelet factor 
Va samples on the Mono-S column was only 50 min and since 
the activity  ratios of the two factor Va peaks  in the plasma 
and platelet samples were approximately the same as those 
observed in purified factor V(a)  preparations (the purification 
of which took 4 days), we conclude that  the heterogeneity of 
factor V does not result from reactions that have occurred 
during the purification procedure. The presence of two forms 
of factor V in fresh plasma and platelet samples indicates 
that  the heterogeneity is an intrinsic  property of factor V. 
Cofactor Activities of the Two Forms of Factor Vu-Expres- 
sion of the cofactor activity of factor Va is dependent on 
direct  interactions with prothrombin, factor Xa, and phos- 
pholipid. In  the factor Va assay (see “Experimental Proce- 
dures”), the reaction conditions are chosen such that factor 
Va is the limiting factor and all other components are  present 
in excess. This means that under  these conditions, differences 
in  protein-protein or protein-lipid interactions between the 
two forms of factor Va may nullify and escape attention? 
To compare the cofactor activities of the two forms of factor 
Va, we have, therefore, performed a kinetic analysis of the 
stimulatory effects of the factor Va preparations on prothrom- 
bin activation  under suboptimal reaction conditions, i.e. at a 
limiting amount of factor Xa  and at  a low concentration of 
phospholipid vesicles containing  a low  mole percentage of PS 
(2 PM DOPS/DOPC, 5/95, mol/mol). Fig. 5 shows that there 
was a rather large difference between the  amounts of factors 
Val and Va2 required for the assembly of a functionally active 
membrane-bound factor Xa . Va  complex. Half-maximal pro- 
thrombinase complex formation was observed at  5.93 nM 
factor Val and 0.45 nM factor Vaz. A double-reciprocal plot of 
these data (Fig. 5B) shows that the rates of prothrombin 
activation attained at  saturating levels of factor Va were 
approximately the same  (Table I), which indicates that  the 
factor Xa. Val and  Xa. Va2 complexes, once they are formed, 
have equal catalytic activities. 
The differences in  factor Xa. Va  complex formation disap- 
peared when the same experiment was performed with phos- 
pholipid vesicles that contained  a high mole percentage of PS 
(i.e. 2 p M  PS/PC, 20/80 mol/mol). On these membranes, half- 
maximal prothrombinase complex formation required 0.047 
nM factor Val and 0.044 nM factor Va2 (Table  I). This exper- 
In the factor Va assay, reaction conditions were such that factor 
Va was present at a limiting concentration, and all other components 
were added in excess. The phospholipid concentration and composi- 
tion (100 p~ PS/PC, 10/90, mol/mol) and  the high factor Xa concen- 
tration (5 nM) ensures full incorporation of factor Va into the mem- 
brane-bound factor Xa. Va complex. Complete incorporation of both 
factors Val and Vaz into  the prothrombinase complex is shown by 
the fact that rates of prothrombin activation were not further in- 
creased when the prothrombin, phospholipid, and factor Xa concen- 
trations in the assay mixture were increased. The validity of this 
assay for quantitating  factor Val and Van preparations is also shown 
by the fact that preparations that were set at the same protein 
concentration on the basis of Am yielded the same concentrations in 
the functional assay. 
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FIG. 3. A, chromatography of factor 
V on Mono-S. 5 ml of purified factor V 
(5 mg) in 10 mM Hepes pH 7.5, 50 mM 
NaCl was applied to a Mono-S column 
(HR 5/5). The column was washed with 
15 ml  of a buffer containing 25 mM 
Hepes pH  7.5,50 mM NH,CI, and 5 mM 
CaC12 and subsequently developed with 
30  ml of a linear gradient from 50 to 1000 
mM NH4CI in 25 mM Hepes pH 7.5 and 
5 mM CaC12. Samples from the column 
fractions were incubated for 1 h at 37  "C 
with thrombin (final concentration, 25 
nM) and  the factor Va generated (0) was 
assayed as described under "Experimen- 
tal Procedures." B, gel electrophoretic 
analysis of factor Va generated in the 
factor V fractions that eluted from the 
Mono-S column. Aliquots (50 pl) from 
the column fractions 64, 66, 72, 76, 78, 
and 82) were activated with thrombin 
(Fig. 3A) and subsequently mixed wih 
12.5 pl of  gel electrophoresis sample 
buffer (19). 20 pl of the gel samples were 
then applied to a 7.5% slab gel and sub- 
jected to SDS-PAGE (19). Sm is a lane 
with starting material (factor V) acti- 
vated with thrombin; M. is a  lane with 
molecular weight markers. The proteins 
on the gel  were stained with Coomassie 
Brilliant Blue R-250. 
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FIG. 4. Chromatography of thrombin-activated plasma on a 
Mono-S  column. Platelet-poor plasma derived from  blood collected 
in citric acid was brought to 5 mM free CaC12 and incubated for 10 
min at 37 "C with thrombin (final concentration  10 nM). The fibrin 
clot that was formed was  removed, and 1 ml  of the serum was diluted 
five times with column buffer (25 mM Hepes pH 7.5, 5 mM CaC12) 
and applied to a Mono-S column (HR 5/5). The column was washed 
with 13 ml of a buffer containing 25 mM Hepes pH 7.5, 150 mM 
NH4C1, and 5 mM CaCI2, and  the proteins bound to  the column were 
subsequently eluted with 15 ml of a  salt  gradient from 50 to 1000 mM 
NH4C1 in 25 mM Hepes pH 7.5 and 5 mM CaC12. Column fractions 
(0.5 ml) were assayed for factor Va activity (0) as described under 
Experimental Procedures." 
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iment  indicates that  the different efficiencies by which factors 
Val and Van incorporate  in the prothrombinase complex are 
likely compensated by an increased binding affinity and  an 
increased number of binding sites for factors Xa and Va on 
membranes containing 20 mole percent of PS (3, 27,  28-31). 
This argumentation  predicts that differences between factors 
Val and Van can also be observed on membranes with 20 mole 
percent of PS, provided that  the experiment is performed at 
a lower phospholipid concentration. Indeed titration of a 
limited amount of factor Xa with factors Val or Va2 on 0.1 
PM PS/PC (20/80, mol/mol) vesicles again showed a differ- 
ence between the two forms of factor Va (Table  I). A t  this 
phospholipid concentration,  a 9-fold higher concentration of 
factor Val was required to obtain half-maximal rates of pro- 
thrombin activation (0.389 nM factor Val versus 0.044 nM 
factor Van). 
With respect to  the different functional properties of factors 
Val and Van, the possibility has  to be ruled out  that factor 
Val lacks functional activity and  that  the cofactor activity of 
factor Val is due to a small (-8%) contamination with factor 
Van. This possibility is excluded by the observations that ( a )  
the  amounts of factor Val and factor Van required for factor 
Xa.Va complex formation on 2 pM Ps/Pc (20/80) were the 
same (Table I),  and ( b )  equal protein  amounts of factors Val 
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TABLE I 
Kinetic analysk of the functional activities of Factors Val and Va, 
Cofactor activities of factors Val and Va, were determined by 
measuring rates of prothrombin  activation at  a limiting factor  Xa 
concentration  in a reaction mixture containing 25 mM Hepes pH 7.5, 
175 mM NaCl, 2 mM CaC12, 5 mg/ml BSA, 3 PM factor Xa, 1 p~ 
prothrombin, varying amounts of factors Val or Va,, and phospholipid 
vesicles as indicated in the Table. Rates of prothrombin activation 
were plotted  against the factor Va concentrations and  and 
VV.,, were obtained by fitting the  data to a hyperbola (see Fig. 5 ) .  
Further experimental conditions are given under  “Experimental Pro- 
cedures.” 
Factor Val 
Phospholipid 
Factor  Va, 
KMv.1 VV.-- KHVIZ V V ~ - -  
nM  nM IIa/min nM  nM IIa/min 
2 p M  Ps/Pc (5/95) 5.93 6.35 0.45 6.15 
2 pM Ps/Pc (20/80) 0.047 18.6 0.044 17.9 
0.1 p M  Ps/Pc (20/80) 0.39 12.8 0.044 13.5 
A 
7 ,  1 . I 
0 ’  I 
[Factor Val (nM) 
0 10 20 30 40 
B 
-2 0 2 4 
l/[Factor Val (nM.’) 
FIG. 5. Comparison of cofactor activities of factors Val and 
Van. Rates of prothrombin activation at limiting factor Xa were 
determined in a reaction mixture containing 25 mM Hepes pH 7.5, 
175 mM NaCl, 2 mM CaC12, 5 mg/ml BSA, 2 p~ phospholipid vesicles 
(DOPS/DOPC, 5/95, mol/mol), 3 pM factor Xa, 1 p~ prothrombin, 
and amounts of factor Val (0) or factor Va, (A) indicated in the 
figure. Further experimental conditions are described under  “Exper- 
imental Procedures.” A, rate of prothrombin activation as a function 
of the concentration factor Val or Va2. The solid lines represent 
hyperbola obtained after  fitting the  data with &(Val) = 5.93 nM and 
VV, = 6.35 nM IIa/min (0) or K,+(Va2) = 0.45 nM and VV, = 6.15 
nM IIa/min (A). B,  double-reciprocal plots of the same  data. 
or Va2 yield the same concentrations in the quantitative 
functional assay.2 
Table I1 summarizes the kinetic parameters for prothrom- 
bin activation determined at saturating concentrations of 
factors Val or Va2. Similar values were obtained for the K,,, 
for prothrombin  and the V, of prothrombin  activation for 
both forms of factor Va. This indicates that factors Val and 
Va2 neither differ in their  interaction with prothrombin nor 
in  their capacity to promote the catalytic  activity of factor  Xa 
but exhibit considerable differences in  their  ability to assem- 
ble into  a membrane-bound factor Xa. Va complex. 
Membrane Binding Properties of Factors Val and Va2”The 
impaired incorporation of factor Val into the membrane- 
TABLE I1 
Kinetic parameters of prothrombin activation 
Rates of prothrombin activation at a limiting factor  Xa  concentra- 
tion were determined  in a reaction mixture containing 25 mM Hepes 
pH 7.5,175 mM NaCl, 2 mM CaCl,, 5 mg/ml BSA, 10 pM phospholipid 
vesicles (DOPS/DOPC, 5/95, mol/mol), 3 PM factor  Xa, 25 nM factor 
Val or factor Vaz, and varying amounts of prothrombin. Kinetic 
parameters (K,,, and V& were obtained by fitting the  data  to  the 
Michaelis-Menten equation using the Enzfitter computer program. 
Further experimental conditions are given under  “Experimental  Pro- 
cedures.’’ 
P M  mol/min/mol  Xa 
Factor Val 0.32 5386 
Factor Vaz 0.16  5687 
0 5 10 15 20 25 30 
[Factor Val (nM) 
FIG. 6. Binding of factors Val and Va, to planar phospho- 
lipid bilayers. Binding of factors Val (0) and Va2 (A) to planar 
phospholipid bilayers (DOPS/DOPC, 20/80, mol/mol) was deter- 
mined by ellipsometry (25 )  in a reaction mixture containing 25 mM 
Hepes pH 7.5, 150 mM NH,Cl, 5 mM CaCl2, and 5 mg/ml BSA. The 
solid lines represent hyperbolas obtained by a non-linear  least-squares 
fit of the data. The binding parameters describing these hyperbola 
are &(Val) = 24  nM and 0.397  pg factor Val bound/cm2 phospholipid 
at  saturating factor Val or Kd(Vaz) = 0.53 nM and 0.364  pg factor Vas 
bound/cm2 phospholipid at  saturating factor Va,. 
bound factor Xa-Va complex most likely results from a de- 
creased affinity for either phospholipid or factor Xa. To 
distinguish between these possibilities, we have determined 
the affinity of both forms of factor Va for PS-containing 
membranes (Fig. 6). Factor Vaz bound with high affinity to 
membranes composed of 20 mole percent of PS in PC. A 
hyperbolic fit of the binding data yielded a Kd of  0.53 nM and 
0.364 pg factor Va2 bound/cm2 phospholipid at saturating 
factor Va. Factor Val had  a much lower affinity for phospho- 
lipid, and, with the  amounts of factor Val available, we were 
unable to add sufficiently high concentrations to achieve 
saturation of the membrane surface (Fig. 6). From a hyper- 
bolic fit of the binding curve, it can be estimated, however, 
that  the interaction between factor Val and  the membrane is 
characterized by a Kd of about 24 nM and 0.397  pg factor Val 
bound/cm2 phospholipid at saturating factor Val. From the 
molecular weights of factor Va (-180,000 Da)  and  the phos- 
pholipid used (-800 Da) and considering that 1 cm2 of a 
bilayer phospholipid surface contains 0.4  pg phospholipid, it 
can be calculated that phospholipid to factor Va ratios at 
saturation  are 227 and 247 for factors Val and Vaz, respec- 
tively. 
These observations show that  the two forms of factor Va 
differ considerably in  their affinity for phospholipids, while 
the number of binding sites for factors Val and Va2 on the 
phospholipid surface are  the same. The large affinity differ- 
ence very likely explains the different cofactor activities of 
factors Val and Va2 in  prothrombin activation. 
DISCUSSION 
Purified  human  factor Va preparations have been reported 
to consist of a heavy chain with M, = 105,000 and  a doublet 
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light chain with M, = 71,000 and = 74,000 (7). The data 
presented in this  paper show that  it is possible to bind factor 
Va to a Mono-S column and  to separate two forms of factor 
Va by developing the column with an NH&1 gradient. The 
peak eluting at  the low salt  concentration consisted of factor 
Va (Va,) with M, = 74,000 light chain, whereas factor Va with 
M ,  FZ 71,000 light chain  (factor  Van)  eluted at a much higher 
salt  concentration. It is likely that  the factor Va bound to  the 
Mono-S column via its light chain, since this subunit is 
considered to be a basic protein that exhibits  a high affinity 
for cation exchangers (3, 11). The elution profile from the 
Mono-S column is, therefore, indicative of a charge difference 
between the light chains of factors Val and Vaz, in  the sense 
that  the light chain of factor Van is more positively charged 
than  the light chain of factor Val. 
The interaction of factor Va with procoagulant membranes 
appears to depend on both hydrophobic interactions (32-35) 
and on electrostatic  interactions between the positively 
charged light chain and negatively charged phospholipids (27, 
30, 36). Considering that electrostatic  interactions  are impor- 
tant for factor Va-membrane association and  that  there may 
be a considerable charge difference between the light chains 
of the two factor Va forms, we hypothesized that factor Val 
may exhibit  a lower affinity for negatively charged membranes 
than factor Van. Direct binding experiments show that  this is 
indeed the case. Factor Vaz binds with a high affinity (Kd = 
0.53  nM) to PS-containing membranes (Ps/Pc,  20/80), 
whereas the affinity of factor Val for such membranes is much 
less (Kd  = 24 nM). The lipid/factor Va ratios (n) at protein 
saturation were approximately the same (n = 227 for factor 
Val and n = 247 for factor Van), which shows that the 
membrane surface contains the same number of binding sites 
for both forms of factor Va. It is difficult to compare these 
binding parameters with literature values, since the interac- 
tion of human factor Va with membranes is not well docu- 
mented, whereas a wide range of binding parameters ( K d  = 
0.05-10 nM and n = 42-250) is reported to describe the 
interaction of bovine factor Va with PC membranes that 
contain 25  mole percent of PS (27, 29-31, 36). 
Factor Va plays an important role in both the assembly and 
expression of the catalytic activity of the prothrombinase 
complex on procoagulant membrane surfaces (1-4). Since 
proper cofactor function requires the binding of factor Va to 
the membrane, it  is  to be expected that  the different affinities 
of factors Val and Van for negatively charged membranes will 
result in different efficiencies to  act  as a cofactor in prothrom- 
bin activation. Kinetic experiments showed that  the cofactor 
function of factor Val is indeed impaired. Much higher 
amounts of factor Val were required for full assembly of the 
prothrombinase (factor Xa. Va) complex at  the membrane 
surface. Once formed, the factor Xa- Val and Xa. Van com- 
plexes exhibit the same catalytic activity in prothrombin 
activation. This  can be inferred from the fact that  the kinetic 
parameters (kat and K,) for prothrombin  activation are sim- 
ilar (Table 11). Differences in efficiencies by which factors 
Val and Van assemble into  a membrane-bound factor Xa. Va 
complex  were observed only on membranes that contain low 
amounts of PS or when prothrombin is activated at low 
phospholipid concentrations. This is not surprising if one 
considers that factor Xa. Va complex formation on the phos- 
pholipid surface is a reflection of the concentrations of sur- 
face-bound factors Va and  Xa (3, 37). At  high mole percent- 
ages  of PS and at high phospholipid concentrations, differ- 
ences between factors Val and Van will  be  nullified when the 
concentration of factor Va binding sites exceeds the Kd values 
for the membrane-factor Va complexes, since this condition 
results  in virtually complete binding of both forms of factor 
Va. 
The heterogeneity in the light chains of factor Va is not  a 
unique property of factor Va but is already present  in factor 
V. It appears that  the purified factor V preparations  and even 
freshly prepared plasma samples and platelet suspensions 
contain two forms of factor V, which, after activation with 
thrombin,  are converted into factors Val and Van. This shows 
that  the heterogeneity is an intrinsic property of factor V and 
is not caused by reactions occurring during the purification 
procedure or to additional peptide bond cleavages that take 
place when factor V is  activated with thrombin. 
Our experiments give no direct insight to the structural 
basis underlying the difference between the light chain regions 
of the two forms of factor V. However, combination of infor- 
mation  presented  in  this  paper with data recently reported by 
Ortel et al. (12) strongly suggests that  the observed heteroge- 
neity originates from the carboxyl-terminal C2 domain of the 
light chain region of factor V. Ortel et al. (12) isolated recom- 
binant human factor V and showed that activation with 
thrombin resulted in the formation of a light chain doublet. 
Activation of mutant molecules that lack the carboxyl-ter- 
minal C2 domain (i.e. amino acid residues 2037-2196)  yield a 
factor Va molecule with a single truncated light chain with 
M, = 62,000. Deletion of the C2 domain caused an essentially 
complete loss of the ability of the  mutant factor Va molecule 
to bind to negatively charged membranes. This indicates that 
the occurrence of two forms of factor Va (Val and  Van) with 
different  affinities for procoagulant membranes results from 
the presence of two light chains with structural differences in 
the C2 domain. The fact that heterogeneity is also observed 
in  the factor V present in freshly prepared platelet  and plasma 
samples and  in  recombinant factor V (12) strongly suggests 
that  the heterogeneity is due to differences in post-ribosomal 
processing or post-ribosomal modification (e.g. glycosylation) 
of the two factor V molecules. Whether the presence of two 
forms of factor V in plasma has a physiologicdl function 
remains to be clarified. 
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